upsid price
return equiti ltm
outlook affirm increas price
top line varian report revenu million versu estim
million consensu estim million oper
segment exceed top-lin expect oncolog system revenu
million versu estim million proton solut
segment deliv million revenu versu estim million
gross oncolog order quarter increas outstand decade-
high report constant currenc proton solut
busi book new order quarter
bottom line varian report non-gaap ep figur quarter
versu expect consensu estim lower-than-
expect gross margin result weigh tariff headwind
primari reason slight ep miss
balanc sheet cash flow varian end quarter cash
equival approxim million debt flow
oper quarter roughli million versu
period last year larg due time certain a/r collect
outlook varian affirm previously-provid financi guidanc
includ revenu growth adjust ep rang
flow oper expect track million
million full-year non-gaap effect tax rate expect
weight averag share count around
million model gener consist manag guidanc
recommend maintain outperform invest rate
share increas price target previou
arriv price target attach multipl adjust ebitda
estim assum million net cash month
revenu mil estimate bold
ep estimate bold
note pleas refer page end
report import disclosur
overal varian medic deliv solid fiscal first quarter overal revenu easili
beat expect consensu non-gaap ep fall slightli short
expect well consensu tariff issu character
manag impact compani level gener line
varian intern expect though net neg impact bit heavier
expect importantli view varian gross order oncolog
quarter whop constant currenc increas dollar
lastli varian affirm previously-provid financi guidanc includ
expect revenu growth non-gaap ep
remind compani deliv non-gaap ep
revenu look revenu oper segment oncolog system revenu came
million easili beat estim million compani
revenu segment increas around versu compar period last year
product revenu appear increas around quarter servic
varian proton solut segment deliv million revenu increas
around versu compar quarter last year estim busi
gross margin oper expens total consolid gross margin came
versu estim oncolog system gener gross
margin improv bp gross margin quarter remain
well corpor averag
non-gaap sg expens quarter came revenu versu
model sg expens benefit one-tim
gain equiti invest expens revenu versu model
profit non-gaap ep came fell short consensu
estim penni miss expect
balanc sheet cash flow varian end quarter cash equival
approxim million debt flow oper total roughli
varian report solid first quarter result view includ rather
larg revenu beat slight non-gaap ep shortfal neg impact
associ tariff million said order momentum
oncolog segment except strong increas constant currenc
report final manag affirm previously-provid financi outlook
believ reiter guidanc seen
investor posit given continu overhang uncertainti relat tariff
issu relat /china trade polici
remind varian financi guidanc includ expect
overal revenu growth adjust ep non-gaap oper margin
oper cash flow million current model
adjust ep revenu growth cash flow expect also consist
varian guidanc
varian believ continu captur market share radiat therapi market
estim grow around innov variou strateg initi
credit recent success think compani busi momentum
past sever quarter undeni certainli believ varian pick share
time-frame manag state believ current momentum could
easili continu
manag state financi drag associ tariff
million total includ million revenu million cost
revenu line million impact unabl mitig varian cost
compani non-gaap ep quarter
varian see million gross impact remain associ tariff
issu includ million provid drag revenu
remind manag previous state compani mitig
gross figur full year million origin million
estim impact variou lever includ suppli chain re-phas
certain project believ varian manag remain confid abil
mitig cost tariff
expect compani tariff mitig effort impact incom
statement second half result non-gaap ep
cadenc weight toward second half consist model
previous varian said total non-gaap ep drag associ issu
mitig effort would equat around guidanc remain accur
believ clearli non-gaap hit associ
tariff taken suspect net impact also heavi
rel remaind though gross impact character
like equal spread throughout remain three quarter
varian continu optimist regard recent format flashforward
consortium studi potenti ultra-high dose rate cancer treatment
flash earli pre-clin work appear excit seem hold promis
amazingli quick treatment throughput attack cancer tumor larg
spare healthi tissu compani state human trial could begin earli
month believ initi could ultim success result
genuin paradigm shift radiat therapi space
varian also briefli touch develop work multimod
adapt radiotherapi suit driven artifici intellig promis
enhanc clinic decision-mak deliveri patient radiat therapi
regimen compani state promis product reson
got sens potenti astro confer octob compani said
hope launch product commerci within next month
quarter oncolog system revenu increas dollar constant
currenc result larg driven revenu growth emea region
asia-pacif region also show growth increas final oncolog busi
america declin difficult growth compar result
prior-year period
oncolog gross order highest decad quarter increas
dollar constant currenc america order million
increas order north america also compani state
experienc robust demand halcyon truebeam strong growth softwar
servic quarter america region
europ middl east india africa region gross oncolog order increas
dollar constant currenc region sixth consecut
double-digit growth perform primarili driven larg tender
gross oncolog order asia-pacif region dollar
constant currenc china cite manag particularli good
quarter said grown doubl digit
varian gross margin within oncolog busi declin bp
quarter chines tariff issu neg impact disappoint result
bp geograph mix also somewhat unfavor term
metric look gross margin continu rel weak versu result
due continu drag associ tariff issu
import note compani guidanc assum relief
provid term tariff throughout balanc thu posit decis
would repres upsid model manag guidanc
compani gener addit halcyon order quarter bring
total sinc product first unveil vienna may order
halcyon quarter place korea emea region
compani continu see strong demand softwar solut revenu
increas quarter varian also disclos softwar custom
base grew quarter state compani rapidplan softwar
continu demonstr good growth
varian proton solut busi gener million revenu
quarter book new busi compani mostli walk back
previou outlook segment could achiev break-even profit
reduc level optim primarili due lack close order quarter
manag expect two seven proton solut order
remind four quarter sinc new order book within
varian proton solut busi margin proton solut segment also remain
well compani averag due part still rel modest footprint
varian continu activ share repurchas activ repurchas
approxim million share quarter share
compani still well three million share remain current share
continu look intern invest meaning capit
alloc prioriti rel share repurchas throughout balanc
said expect compani continu engag rel modest amount
share repurchas throughout rest year
maintain outperform invest rate share
increas price target arriv price target attach
multipl adjust ebitda estim assum million
net cash month
revenu
interest incom net
 revenu
sg revenu
pre-shar repo chg wc
million except per share data
ex pe te tp rfo rm th rk th xt nt hs
 im ro co fu ta ls
 nd rv lu cu rr nt
ex pe te rfo rm ou ne th th rk ov th ex mo th
lo -te rm te tia ts ne -te rm ca ta yst
fa irl lu cu rr nt
ex pe te rp rfo rm th ar ke ne th
fu al r- va ue cu le
 el ri ta et fo thi co se /e itd th
ri ks th ou ta rg ric il ie lu mi te fai ur
th om ou rn stim te
th fo st ra tin fo co ni co ar ri gto es rch ia te
 se te mp es th ov ra th mb co ni ra te
 et pr se te co ie th co ag
co th ra li st ls ec er ba rr se rc
ci te ro id stm nk ng rv ic es thi th la th
 th co ie th tp er ra ti th co ie
th ad ar pe fo ra ti th mp es
na ly tif ic ion th ea ch yst sp si le fo th ra tio th se rc rt ch pe tu sk fa rti fi
th ie th pa se ur iti xp se th cc ra te ly fl ct rs al io th yst ls
ce ti fi es th rt co sa tio ctl ir ec tli ate th ci fic co da ti ie co ta th rt
 se rc ly st lu tho nv lv th pa ti th po ce co ns tio ti th th firm
nv stm cti vi tie ly st om sa ti ch de la se ro fa ct nc lu
sto ri ce rfo iti ys tor cl ie fe ba th ra ofi ta il iti fi rm ic im cte
 th fi rm si ss ac tiv ti nc lu th er th sti tuti iti tra stm ba se vi ce
tme ki se rv ic de fi un le lu th thi ti rw ri te
 th se li gr ec ri tie nd riti th ly st ns ib fo th rt mi ch pe tu sk mb th yst
 se ld th mm th sd ati te ru le th ro ib se rc ly st
fro tra cu iti es co er ri ci fie tim ri ds nd fte th bl ic tio ea ch rt
 ar ri gto ea ch ss ci te ful l- se rv ic fin ia se rv ic fi rm th ffe rs va ie ty se rv ic ro ct cl ie ts
tor ul ss th rri gt ar ch ek ng il ek stm nk ng oth bu el tio hi th th
co ie nd ts es rc ra ar ri gto se rc ce stm -r el te co en tio fro thi
co th th pa th xp ct thi th thr mo th
barrington research associ inc finra-regist broker/deal clear nation financi nf
fulli disclos basi conveni client offer sever way client facilit payment
trade barrington research order may place trade desk
trader michael hutchison head trader christoph pari email address
instant messeng address brrrmh
trade broker trade may also stepped-in barrington research trade execut broker
commiss share arrang barrington commiss share agreement numer broker wall
street complet list commiss share program barrington research particip pleas contact
salesperson trade desk
follow list provid barrington research trade alloc settlement id nf dtc code execut
question trade set account relat inform pleas call trade depart
inform contain herein obtain sourc believ reliabl guarante accuraci complet
opinion estim reflect best judgment report date subject chang without notic report intend inform
purpos constitut offer solicit buy sell secur barrington research associ inc affili offic
analyst employe may time time posit secur refer herein barrington research associ inc may act
princip agent buyer seller purchas sale secur mention report barrington research associ
inc may provid may seek provid invest bank servic compani mention report report may
reproduc form without prior written consent barrington research associ inc right reserv member finra/sipc
